Suzuki Norihiko, Nakagawa Fumio, Nukatsuka Mamoru, Fukushima Masakazu
Tokushima Research Center, Taiho Pharmaceutical Co., Ltd., Tokushima 771-0194, Japan.
Exp Ther Med. 2011 May;2(3):393-397. doi: 10.3892/etm.2011.244. Epub 2011 Mar 21.
TAS-102 is an oral anticancer drug composed of trifluorothymidine (TFT) and TPI (an inhibitor of thymidine phosphorylase that strongly inhibits the biodegradation of TFT). Similar to 5-fluorouracil (5FU) and 5-fluoro-2'-deoxyuridine (FdUrd), TFT also inhibits thymidylate synthase (TS), a rate-limiting enzyme of DNA biosynthesis, and is incorporated into DNA. TFT exhibits an anticancer effect on colorectal cancer cells that have acquired 5FU and/or FdUrd resistance as a result of the overexpression of TS. Therefore, we examined the mode of action of TFT-induced DNA damage after its incorporation into DNA. When HeLa cells were treated with TFT, the number of ring-open aldehyde forms at apurinic/apyrimidinic sites increased in a dose-dependent manner, although we previously reported that no detectable excisions of TFT paired to adenine were observed using uracil DNA glycosylases, thymine DNA glycosylase or methyl-CpG binding domain 4 and HeLa whole cell extracts. To investigate the functional mechanism of TFT-induced DNA damage, we measured the phosphorylation of ATR, ATM, BRCA2, chk1 and chk2 in nuclear extracts of HeLa cells after 0, 24, 48 or 72 h of exposure to an IC(50) concentration of TFT, FdUrd or 5FU using Western blot analysis or an enzyme-linked immunosorbent assay (ELISA). Unlike FdUrd and 5FU, TFT resulted in an earlier phosphorylation of ATR and chk1 proteins after only 24 h of exposure, while phosphorylated ATM, BRCA2 and chk2 proteins were detected after more than 48 h of exposure to TFT. These results suggest that TFT causes single-strand breaks followed by double-strand breaks in the DNA of TFT-treated cells. TFT (as TAS-102) showed a more potent antitumor activity than oral 5FU on CO-3 colon cancer xenografts in mice, and such antitumor potency was supported by the increased number of double-strand breaks occurring after single-strand breaks in the DNA of the TFT-treated tumors. These results suggest that TFT causes single-strand breaks after its incorporation into DNA followed by double-strand breaks, resulting in DNA damage. This effect of TFT on DNA may explain its potent anticancer activity in cancer therapy.
TAS-102是一种口服抗癌药物,由三氟胸苷(TFT)和TPI(胸苷磷酸化酶抑制剂,可强烈抑制TFT的生物降解)组成。与5-氟尿嘧啶(5FU)和5-氟-2'-脱氧尿苷(FdUrd)类似,TFT也抑制胸苷酸合成酶(TS),这是DNA生物合成的限速酶,并可掺入DNA中。TFT对因TS过表达而获得5FU和/或FdUrd抗性的结肠癌细胞具有抗癌作用。因此,我们研究了TFT掺入DNA后诱导DNA损伤的作用方式。当用TFT处理HeLa细胞时,尽管我们之前报道使用尿嘧啶DNA糖基化酶、胸腺嘧啶DNA糖基化酶或甲基-CpG结合结构域4以及HeLa全细胞提取物未观察到与腺嘌呤配对的TFT有可检测到的切除,但无嘌呤/无嘧啶位点的开环醛形式数量呈剂量依赖性增加。为了研究TFT诱导DNA损伤的功能机制,我们使用蛋白质印迹分析或酶联免疫吸附测定(ELISA),在暴露于IC(50)浓度的TFT、FdUrd或5FU 0、24、48或72小时后,测量HeLa细胞核提取物中ATR、ATM、BRCA2、chk1和chk2的磷酸化情况。与FdUrd和5FU不同,TFT仅在暴露24小时后就导致ATR和chk1蛋白更早地磷酸化,而在暴露于TFT超过48小时后才检测到磷酸化的ATM、BRCA2和chk2蛋白。这些结果表明,TFT在TFT处理的细胞DNA中导致单链断裂,随后是双链断裂。TFT(作为TAS-102)在小鼠CO-3结肠癌异种移植模型中显示出比口服5FU更强的抗肿瘤活性,并且这种抗肿瘤效力得到了TFT处理的肿瘤DNA中单链断裂后双链断裂数量增加的支持。这些结果表明,TFT掺入DNA后导致单链断裂,随后是双链断裂,从而导致DNA损伤。TFT对DNA的这种作用可能解释了其在癌症治疗中的强大抗癌活性。